PureTech Announces Issuance of U.S. Patent Covering Compositions of Matter for Immuno-Oncology Program Targeting Galectin-9
09 Julio 2019 - 1:00AM
Business Wire
Fully human, potentially first-in-class,
monoclonal antibody designed to target a fundamental
immunosuppressive mechanism in hard-to-treat cancers
PureTech Health plc (LSE: PRTC) (“PureTech”), an advanced
biopharmaceutical company developing novel medicines for
dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced
that the United States Patent and Trademark Office (USPTO) has
issued U.S. Patent No. 10,344,091 to support the Company’s internal
immuno-oncology product candidate, LYT-200. The patent covers
compositions of matter directed to fully human anti-galectin-9
antibodies, which PureTech intends to develop for historically
difficult-to-treat cancers including pancreatic, colorectal, and
cholangiocarcinoma, among other cancer types. PureTech intends to
file an investigational new drug (IND) application for LYT-200 in
the first half of 2020.
“PureTech’s galectin-9 antibody has been designed to address the
challenges encountered with current immuno-oncology treatments due
to redundancies in the immunosuppressive tumor microenvironment.
Our now patented antibody composition leverages a new mechanism of
action to disrupt the immunosuppressive environment, potentially
enabling the body’s immune system to attack cancers that have
historically been hard to treat,” said Joe Bolen, Ph.D., chief
scientific officer of PureTech. “This patent provides important
coverage for our immuno-oncology program, and we look forward to
continuing the development of LYT-200 to address the tremendous
patient need that exists.”
Galectin-9 induces robust immunosuppression that allows tumors
to evade immune system attack. It is a foundational immune
modulator that is expressed in the tumor microenvironment, on tumor
cells, and in the blood of cancer patients, globally inducing and
maintaining immunosuppression in cancer. High galectin-9 expression
has been demonstrated in a number of patient tumor samples,
including those that do not respond well to current checkpoint
inhibitors. By blocking galectin-9, PureTech’s potentially
first-in-class, fully human, monoclonal antibody is designed to
intercept the immunosuppressive pathways that galectin-9
stimulates, potentially enabling an immune-mediated response
against tumors. While existing therapies have not been sufficiently
effective in the treatment of aggressive tumors, PureTech’s
approach has shown favorable drug properties and safety in
pre-clinical models, and it is being explored as both a
single-agent and in combination with other modalities for cancer
treatment, including other immunotherapies and chemotherapies.
About LYT-200 PureTech’s immuno-oncology program,
LYT-200, is a fully human, potentially first-in-class, IgG4
monoclonal antibody designed to target galectin-9, which is a
fundamental immunosuppressive mechanism in hard-to-treat cancers
such as pancreatic, colorectal, and cholangiocarcinoma, among other
tumor types. LYT-200 has demonstrated proof-of-concept in both
mouse and preclinical human cancer models, indicating that
targeting galectin-9 activates T cells in tumors and reduces tumor
growth, which could significantly extend survival. These data
suggest that LYT-200 has strong potential to be used as both a
monotherapy and in combination with existing immuno-oncology
therapies. PureTech intends to file an investigational new drug
(IND) application for LYT-200 in the first half of 2020.
About PureTech PureTech (LSE: PRTC) is an advanced
biopharmaceutical company developing highly differentiated
medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis. The
Company has gained deep insights into the connection between these
systems and the resulting role in diseases that have been resistant
to established therapeutic approaches. By harnessing this emerging
field of human biology, PureTech is developing new categories of
medicines with the potential to have great impact on people with
serious disorders.
PureTech is advancing a rich pipeline of innovative therapies
with an unbiased, nimble, and capital efficient R&D model
across its affiliates and its internal R&D pipeline. PureTech’s
pipeline comprises more than two dozen product candidates,
including several clinical-stage programs, one product that has
been cleared by the US Food and Drug Administration (FDA), and a
second product candidate that has been filed with the FDA for
review. The PureTech pipeline includes ground-breaking platforms
and therapeutic candidates that were developed in collaboration
with some of the world’s leading experts.
PureTech’s internal pipeline is centered on lymphatic targeting
and tissue-selective immunomodulation for the potential treatment
of immune and central nervous system disorders, lymphatic
conditions, and cancers. The company is advancing multiple
platforms to enable oral administration of therapies directly into
the lymphatic system, regulate lymphatic flow and function, and
target immunosuppressive mechanisms in oncology. For more
information, visit www.puretechhealth.com or connect with us on
Twitter @puretechh.
Forward Looking Statement This press release contains
statements that are or may be forward-looking statements, including
statements that relate to the company's future prospects,
developments and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown
risks and uncertainties that could cause actual results,
performance and achievements to differ materially from current
expectations, including, but not limited to, those risks and
uncertainties described in the risk factors included in the
regulatory filings for PureTech Health plc. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, neither the company
nor any other party intends to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190708005747/en/
Investors Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com
U.S. Media Tom Donovan +1 857 559 3397
tom@tenbridgecommunications.com
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024